ClinicalTrials.Veeva
Menu

Find clinical trials for Prostate Cancer in Valencia, VC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Prostatic Cancer
Cancer
Carcinoma
Hypersensitivity
Endometrial Cancer
Recurrence
Adenocarcinoma

Prostate Cancer trials near Valencia, VC, ESP:

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisi...

Enrolling
Prostatic Disease
mCRPC (Metastatic Castration-resistant Prostate Cancer)
Drug: Gedatolisib
Drug: Darolutamide

Phase 1, Phase 2

Celcuity

Valencia, Spain and 12 other locations

primary trial objective is to demonstrate that ODM-201 produces prostate-specific antigen (PSA) response rates at 24 weeks (defined as ≥80% ...

Active, not recruiting
Prostate Cancer
Drug: ADT
Drug: ODM-201

Phase 2

European Organisation for Research and Treatment of Cancer (EORTC)

Valencia, Spain and 11 other locations

to evaluate the efficacy and safety of talazoparib (PF-06944076) in combination with enzalutamide in patients with metastatic hormone-naïve prostate...

Active, not recruiting
Metastatic Prostate Cancer
Drug: Enzalutamide
Drug: Talazoparib

Phase 2

MedSIR

Valencia, Spain and 7 other locations

Metastatic prostate cancer is an incurable disease that typically spreads beyond the prostate. The standard of care is to ...

Active, not recruiting
Metastatic Hormone-sensitive Prostate Cancer
Drug: ADT (androgen deprivation therapy)
Drug: Nivolumab 10 MG/ML

Phase 2, Phase 3

Spanish Oncology Genito-Urinary Group

Valencia, Spain and 29 other locations

Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate...

Enrolling
Prostate Cancer
Drug: Saruparib (AZD5305)
Drug: Darolutamide

Phase 1

AstraZeneca
AstraZeneca

Valencia, Spain and 19 other locations

to as AAA617. The study also seeks to further characterize (as possible) any other serious adverse reaction(s) in the long-term in adults with prostate...

Enrolling
Prostate Cancer
Drug: AAA617

Phase 4

Novartis
Novartis

Valencia, Spain and 53 other locations

docetaxel with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate...

Active, not recruiting
Metastatic Prostate Cancer
Other: Androgen Deprivation Therapy
Drug: abiraterone acetate

Phase 3

Unicancer
Unicancer

Valencia, Spain and 76 other locations

of ADT +/- darolutamide in castration-naïve de novo metastatic prostate cancer patients with vulnerable functional ability who have...

Enrolling
Prostate Cancer Metastatic
Drug: Androgen deprivation therapy
Drug: Darolutamide 300 mg

Phase 3

Unicancer
Unicancer

Valencia, Spain and 89 other locations

The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate...

Active, not recruiting
Prostatic Neoplasms
Drug: Apalutamide
Drug: Placebo

Phase 3

Aragon Pharmaceuticals

Valencia, Spain and 388 other locations

compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate...

Begins enrollment in 1 month
Metastatic Castration-resistant Prostate Cancer
Drug: Docetaxel
Drug: Abiraterone

Phase 3

Celgene
Celgene

València, Spain and 229 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems